Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
| Author | |
|---|---|
| Abstract |
:
The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days. |
| Year of Publication |
:
2022
|
| Journal |
:
The New England journal of medicine
|
| Volume |
:
386
|
| Issue |
:
23
|
| Number of Pages |
:
2188-2200
|
| Date Published |
:
2022
|
| ISSN Number |
:
0028-4793
|
| URL |
:
https://www.nejm.org/doi/10.1056/NEJMoa2116620?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
|
| DOI |
:
10.1056/NEJMoa2116620
|
| Short Title |
:
N Engl J Med
|
| Download citation |
